On Friday 30 September, 2016, GlaxoSmithKline Consumer Nigeria PLC announced the completion of its divestment from the drinks bottling and distribution business to Suntory Beverage & Food Nigeria Limited (SBFN). Following the approval from its shareholders and the Nigeria Securities & Exchange Commission (SEC), GSK has transferred the ownership of the drinks business in Nigeria to Suntory Beverage & Food Nigeria Ltd effective 1st October 2016.
The new GSK Consumer Health Company (retained business) consist of the Consumer Healthcare Wellness, Oral Healthcare and Nutrition categories and Pharmaceutical business. The retained brands include Sensodyne, Macleans, Panadol, Horlicks, Andrew Liver Salts, Voltaren, Otrivin and CAC 1000. The company will continue to be listed on the Nigeria Stock Exchange (NSE)
Subsequent to the approval of the divestment from the drinks business at the Extraordinary General Meeting of 4th July 2016, GSK declared a special dividend of 60k per share. Dividend warrants for the special dividend declared by the company will be posted on 12th October 2016 to holders of shares whose name appear in the register of members at close of business on 30th September 2016.
